Free Trial
NASDAQ:SWTX

SpringWorks Therapeutics Q2 2023 Earnings Report

SpringWorks Therapeutics logo
$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.26
Beat/Miss
Beat by +$0.01
One Year Ago EPS
-$1.41

SpringWorks Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SpringWorks Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Wednesday, August 2, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

SpringWorks Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

SpringWorks Therapeutics Earnings Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More SpringWorks Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SpringWorks Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SpringWorks Therapeutics and other key companies, straight to your email.

About SpringWorks Therapeutics

SpringWorks Therapeutics (NASDAQ:SWTX), Inc. is a clinical‐stage biopharmaceutical company dedicated to developing precision therapies for patients living with rare diseases and cancer. Leveraging its expertise in targeted molecular pathways, the company focuses on advancing novel small‐molecule inhibitors and biologics designed to address underlying genetic drivers. SpringWorks’ mission is to translate cutting‐edge science into effective, well‐tolerated treatments that fill critical unmet medical needs.

The company’s pipeline features several late‐stage programs, including mirdametinib (PD-0325901), a selective MEK inhibitor being evaluated for neurofibromatosis type 1 plexiform neurofibromas, and nirogacestat, an oral gamma secretase inhibitor in development for desmoid tumors. In addition, SpringWorks is exploring seclidemstat, an LSD1 inhibitor targeting Ewing sarcoma and other hematologic malignancies. These core assets stem from strategic collaborations and in-licensing agreements, positioning SpringWorks to advance multiple registrational studies in both the United States and Europe.

Founded in 2017 as a spin-out from a global pharmaceutical company, SpringWorks is headquartered in Stamford, Connecticut, with research and development facilities in North America and Europe. The company conducts multi‐center clinical trials across the U.S., Canada, Australia and key European markets. By partnering with academic institutions and patient advocacy groups, SpringWorks ensures broad access to clinical programs and collaborates on real‐world evidence initiatives.

Under the leadership of President and Chief Executive Officer Saqib Islam and Chief Medical Officer Jan Ewbank, SpringWorks maintains a seasoned management team with deep experience in oncology, rare diseases and clinical development. The board of directors comprises industry veterans and patient advocacy representatives, guiding strategic decision‐making as SpringWorks advances its mission to deliver transformative therapies for underserved patient populations.

View SpringWorks Therapeutics Profile

More Earnings Resources from MarketBeat